Journal Article
. 2019 Aug; 24(16):2865.
doi: 10.3390/molecules24162865.

Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model

Thomas Mueller 1 Juana Freystein 2 Henrike Lucas 3 Hans-Joachim Schmoll 4 
  • PMID: 31394786
  •     27 References
  •     4 citations


Vascular endothelial growth factor (VEGF) inhibition by the addition of bevacizumab to the chemotherapy regimen of metastatic colorectal cancer leads to an improved outcome. However, anti-angiogenic tumor therapy targeting a single factor may be limited by complementary mechanisms. Angiopoietin-2 (Ang-2, ANGPT2) is another important factor that cooperates with VEGF to drive tumor angiogenesis. It was shown that high Ang-2 levels are associated with a poor clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Therefore, combined inhibition of VEGF and Ang-2 was supposed to improve anti-angiogenic therapy. Here, we evaluated the efficacy of a bispecific antibody (CrossMab) co-targeting VEGF and Ang-2 in combination with chemotherapy in a chemoresistant colorectal carcinoma model. Antitumor activity was evaluated in athymic nude mice bearing subcutaneous DLD1 xenograft tumors and treated with anti-VEGF (B20), anti-Ang-2 (LC06) and anti-VEGF/Ang-2 (CrossMab) antibodies. Chemotherapy consisted of 5-FU and irinotecan. Resected tumors were analyzed immunohistochemically. First, an impact of targeting each single factor but also a clear advantage of co-targeting both factors could be demonstrated. Accordingly, tumor tissue showed strong staining for VEGF and Ang-2. Chemotherapy alone was less effective. Efficient tumor growth inhibition could be achieved by treatment with anti-VEGF/chemotherapy, single CrossMab and CrossMab/chemotherapy, which resulted in 3 out of 10, 6 out of 10 and 10 out of 10 complete responses, respectively, during seven weeks. Complete retarded tumors were characterized by massive intratumoral necrosis surrounded by layers of vital tumor cells and connective tissue with CD31-positive vessels at the periphery. In some cases, a distinct feature known as vessel co-option could be observed. In conclusion, the data from this model clearly support the strategy of co-targeting VEGF and Ang-2 and further demonstrate the beneficial impact of co-treatment with chemotherapy. The clear superiority of the CrossMab-containing regimen compared to clinical standard anti-VEGF/chemotherapy warrants further analyses in other models.

Keywords: ANGPT2; Ang-2; CrossMab; VEGF; anti-angiogenic therapy; bevacizumab; bispecific antibody; colorectal cancer; vanucizumab.

Expression of angiopoietins and its clinical significance in non-small cell lung cancer.
Fumihiro Tanaka, Shinya Ishikawa, +5 authors, Hiromi Wada.
Cancer Res, 2002 Dec 04; 62(23). PMID: 12460935
Angiopoietins in tumours: the angiogenic switch.
Catherine R Tait, Pamela F Jones.
J Pathol, 2004 Aug 13; 204(1). PMID: 15307132
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.
Rakesh K Jain.
Science, 2005 Jan 08; 307(5706). PMID: 15637262
Highly Cited. Review.
Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.
Wei-Ching Liang, Xiumin Wu, +8 authors, Germaine Fuh.
J Biol Chem, 2005 Nov 10; 281(2). PMID: 16278208
Highly Cited.
Angiogenesis as a therapeutic target.
Napoleone Ferrara, Robert S Kerbel.
Nature, 2005 Dec 16; 438(7070). PMID: 16355214
Highly Cited. Review.
Angiogenesis: an organizing principle for drug discovery?
Judah Folkman.
Nat Rev Drug Discov, 2007 Mar 31; 6(4). PMID: 17396134
Highly Cited. Review.
Modes of resistance to anti-angiogenic therapy.
Gabriele Bergers, Douglas Hanahan.
Nat Rev Cancer, 2008 Jul 25; 8(8). PMID: 18650835    Free PMC article.
Highly Cited. Review.
Pathways mediating resistance to vascular endothelial growth factor-targeted therapy.
Lee M Ellis, Daniel J Hicklin.
Clin Cancer Res, 2008 Oct 18; 14(20). PMID: 18927275
Targeting the ANGPT-TIE2 pathway in malignancy.
Hanhua Huang, Abhijit Bhat, Gary Woodnutt, Rodney Lappe.
Nat Rev Cancer, 2010 Jul 24; 10(8). PMID: 20651738
Highly Cited. Review.
Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy.
V Goede, O Coutelle, +11 authors, U T Hacker.
Br J Cancer, 2010 Oct 07; 103(9). PMID: 20924372    Free PMC article.
Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg.
Cell, 2011 Mar 08; 144(5). PMID: 21376230
Highly Cited. Review.
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies.
Wolfgang Schaefer, Jörg T Regula, +13 authors, Christian Klein.
Proc Natl Acad Sci U S A, 2011 Jun 22; 108(27). PMID: 21690412    Free PMC article.
Highly Cited.
The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review.
Limor Amit, Irit Ben-Aharon, +2 authors, Salomon Stemmer.
PLoS One, 2013 Jan 26; 8(1). PMID: 23349675    Free PMC article.
Systematic Review.
A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.
Markus Thomas, Yvonne Kienast, +12 authors, Christian Klein.
PLoS One, 2013 Feb 14; 8(2). PMID: 23405099    Free PMC article.
Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.
Yvonne Kienast, Christian Klein, +12 authors, Markus Thomas.
Clin Cancer Res, 2013 Oct 08; 19(24). PMID: 24097868
Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.
Stefano Kim, Erion Dobi, +12 authors, Christophe Borg.
BMC Cancer, 2014 Jan 01; 13. PMID: 24373251    Free PMC article.
Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer.
Hanna Sallinen, Tommi Heikura, +4 authors, Maarit Anttila.
BMC Cancer, 2014 Sep 24; 14. PMID: 25245329    Free PMC article.
Diagnostic and prognostic potential of serum angiopoietin-2 expression in human breast cancer.
Ping Li, Quanyong He, Chenqun Luo, Liyuan Qian.
Int J Clin Exp Pathol, 2015 Mar 11; 8(1). PMID: 25755760    Free PMC article.
VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside.
Marlous Arjaans, Carolina P Schröder, +3 authors, Elisabeth G E de Vries.
Oncotarget, 2016 Jan 21; 7(16). PMID: 26789111    Free PMC article.
Highly Cited. Review.
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.
Jonas Kloepper, Lars Riedemann, +24 authors, Rakesh K Jain.
Proc Natl Acad Sci U S A, 2016 Apr 05; 113(16). PMID: 27044098    Free PMC article.
Highly Cited.
The use of CrossMAb technology for the generation of bi- and multispecific antibodies.
Christian Klein, Wolfgang Schaefer, Jörg T Regula.
MAbs, 2016 Jun 11; 8(6). PMID: 27285945    Free PMC article.
Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.
Sophia Frentzas, Eve Simoneau, +28 authors, Andrew R Reynolds.
Nat Med, 2016 Nov 01; 22(11). PMID: 27748747    Free PMC article.
Highly Cited.
Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
Victoria L Bridgeman, Peter B Vermeulen, +19 authors, Andrew R Reynolds.
J Pathol, 2016 Nov 20; 241(3). PMID: 27859259    Free PMC article.
Highly Cited.
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.
Martina Schmittnaegel, Nicolò Rigamonti, +8 authors, Michele De Palma.
Sci Transl Med, 2017 Apr 14; 9(385). PMID: 28404865
Highly Cited.
First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors.
Manuel Hidalgo, Maria Martinez-Garcia, +20 authors, Oliver Krieter.
Clin Cancer Res, 2017 Dec 09; 24(7). PMID: 29217526
Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.
Yoshiro Itatani, Kenji Kawada, Takamasa Yamamoto, Yoshiharu Sakai.
Int J Mol Sci, 2018 Apr 20; 19(4). PMID: 29670046    Free PMC article.
Highly Cited. Review.
Vessel co-option in cancer.
Elizabeth A Kuczynski, Peter B Vermeulen, +2 authors, Andrew R Reynolds.
Nat Rev Clin Oncol, 2019 Mar 01; 16(8). PMID: 30816337
Highly Cited. Review.
Comprehensive review of targeted therapy for colorectal cancer.
Yuan-Hong Xie, Ying-Xuan Chen, Jing-Yuan Fang.
Signal Transduct Target Ther, 2020 Apr 17; 5(1). PMID: 32296018    Free PMC article.
Targeting Tumor-Associated Macrophages in Anti-Cancer Therapies: Convincing the Traitors to Do the Right Thing.
Cristina Belgiovine, Elisabeth Digifico, +2 authors, Fernando Torres Andón.
J Clin Med, 2020 Oct 15; 9(10). PMID: 33050070    Free PMC article.
A Correlative Study Between IVIM-DWI Parameters and the Expression Levels of Ang-2 and TKT in Hepatocellular Carcinoma.
Jing Zheng, Xue Qin Gong, +9 authors, Xiao Ming Zhang.
Front Oncol, 2021 Feb 02; 10. PMID: 33520706    Free PMC article.